The use of ADT is the treatment of choice for advanced, metastatic prostate cancer as long as the cancer is responsive to the blockade. The theory goes that the suppression of circulating testosterone, which fuels prostate-cancer growth, whether by surgical castration (orchiectomy) or castration with testosterone-blocking drugs slows down the progression of the prostate cancer. [...]
Musa Mayer a breast cancer advocate has written an article in the Journal of Clinical Oncology that will be of interest to those who work as prostate cancer advocates. The first few paragraphs are reproduced below. In the years since 1989, when I was diagnosed with breast cancer, the advocacy movement has matured, and many [...]
CAUTION, some doctors use estrogen patches as a form of first line hormone blockade therapy for the treatment of prostate cancer. However, scientists from Weill Cornell Medical College, New York City have described the hormone estrogen as a potential key negative player in about half of all prostate cancers. Researchers have found that Estrogen-linked signaling [...]
At the recent American Association of Cancer Researchers (AACR,) there was a shocking poster presentation that demonstrated that mice that exercised experienced implanted prostate cancer tumor grow that was twice as fast than did those mice who were restricted from exercising! The study was conducted by the Duke Comprehensive Cancer Center (DCCC) and the Duke [...]
Federal Advocacy Update that you need to become involved with: There are three resolutions that NPCC is currently educating legislators about: H.Res 672 is sponsored by Doris Matui's office (CA-5) and it supports the goals and ideals of National Prostate Cancer Awareness Month in September. This resolution recognizes the main issues surrounding the lack of [...]